Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Head and Neck Neoplasms 408Squamous Cell Carcinoma of Head and Neck 326Thyroid Neoplasms 104Carcinoma, Non-Small-Cell Lung 85Neoplasms 66Oropharyngeal Neoplasms 59Carcinoma, Squamous Cell 59Melanoma 56Lung Neoplasms 47Neoplasm Metastasis 44Mouth Neoplasms 43Breast Neoplasms 42Laryngeal Neoplasms 39Thyroid Cancer, Papillary 36Salivary Gland Neoplasms 35Colorectal Neoplasms 35Ovarian Neoplasms 33Carcinoma, Renal Cell 33Esophageal Neoplasms 32Urinary Bladder Neoplasms 30Stomach Neoplasms 30Tongue Neoplasms 28Nasopharyngeal Neoplasms 28Uterine Cervical Neoplasms 27Carcinoma 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 24Sarcoma 24Carcinoma, Medullary 24Recurrence 22

Interventions

spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Spinocerebellar Degenerations × Head & Neck × Clear all
NCT03207867 2024-10-09

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Novartis

Phase 2 Terminated
315 enrolled 73 charts
BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Pancreatic Neoplasms, Spinocerebellar Degenerations, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡